10/21/2011

The FDA will take an additional three months to review Elan and Biogen Idec's label change for multiple sclerosis drug Tysabri. The updated warning recommends assessment of a patient's anti-JC virus antibody to determine risk for progressive multifocal leukoencephalopathy.

Related Summaries